Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma

Hao Wei Teng, Hsei Wei Wang, Wei Ming Chen, Ta Chung Chao, Yao Yu Hsieh, Chi Hsiu Hsih, Cheng Hwai Tzeng, Paul Chih Hsueh Chen, Chueh Chuan Yen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background We aimed to study the prevalence and prognostic influence of epidermal growth factor receptor (EGFR) and its downstream effectors in synovial sarcoma (SS). Objectives and Methods The tissue blocks from 30 patients were obtained. Expression of EGFR and phosphatase and tensin homolog (PTEN) were examined by immunohistochemistry, and mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, V-raf murine sarcoma viral oncogene homolog B1 (BRAF) exon 15, phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA) exons 9, 20, and PTEN exons 5-9 were analyzed by direct sequencing. Results: EGFR overexpression and PTEN deletion were found in 63.3% and 46.7% of patients. Sequence analysis failed to demonstrate mutations of KRAS and BRAF. However, an E545A point mutation in exon 9 of PI3KCA was found in 2 of the 30 (6.7%) cases and 4 point mutations in exon 5 (E99K, D106N), intro 6 to exon 7 (AATA(G)), and exon 9 (A359T) of PTEN were found in 2 of the 30 (6.7%) cases. PTEN loss was significantly more frequent in cases of trunk tumors, and the overexpression of EGFR was significantly more prevalent in patients who were 35 or older. Conclusions: PTEN deletion was associated with poor survival.

Original languageEnglish
Pages (from-to)773-781
Number of pages9
JournalJournal of Surgical Oncology
Volume103
Issue number8
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Fingerprint

Synovial Sarcoma
Epidermal Growth Factor Receptor
Exons
Phosphoric Monoester Hydrolases
Class Ia Phosphatidylinositol 3-Kinase
Oncogenes
Point Mutation
Sarcoma
Mutation
Sequence Analysis
Tensins
Cross-Sectional Studies
Immunohistochemistry
Survival

Keywords

  • BRAF
  • EGFR
  • KRAS
  • PI3KCA
  • PTEN
  • synovial sarcoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. / Teng, Hao Wei; Wang, Hsei Wei; Chen, Wei Ming; Chao, Ta Chung; Hsieh, Yao Yu; Hsih, Chi Hsiu; Tzeng, Cheng Hwai; Chen, Paul Chih Hsueh; Yen, Chueh Chuan.

In: Journal of Surgical Oncology, Vol. 103, No. 8, 06.2011, p. 773-781.

Research output: Contribution to journalArticle

Teng, HW, Wang, HW, Chen, WM, Chao, TC, Hsieh, YY, Hsih, CH, Tzeng, CH, Chen, PCH & Yen, CC 2011, 'Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma', Journal of Surgical Oncology, vol. 103, no. 8, pp. 773-781. https://doi.org/10.1002/jso.21852
Teng, Hao Wei ; Wang, Hsei Wei ; Chen, Wei Ming ; Chao, Ta Chung ; Hsieh, Yao Yu ; Hsih, Chi Hsiu ; Tzeng, Cheng Hwai ; Chen, Paul Chih Hsueh ; Yen, Chueh Chuan. / Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. In: Journal of Surgical Oncology. 2011 ; Vol. 103, No. 8. pp. 773-781.
@article{1cdbada87d7a4b84bfe3c373238fdb7a,
title = "Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma",
abstract = "Background We aimed to study the prevalence and prognostic influence of epidermal growth factor receptor (EGFR) and its downstream effectors in synovial sarcoma (SS). Objectives and Methods The tissue blocks from 30 patients were obtained. Expression of EGFR and phosphatase and tensin homolog (PTEN) were examined by immunohistochemistry, and mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, V-raf murine sarcoma viral oncogene homolog B1 (BRAF) exon 15, phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA) exons 9, 20, and PTEN exons 5-9 were analyzed by direct sequencing. Results: EGFR overexpression and PTEN deletion were found in 63.3{\%} and 46.7{\%} of patients. Sequence analysis failed to demonstrate mutations of KRAS and BRAF. However, an E545A point mutation in exon 9 of PI3KCA was found in 2 of the 30 (6.7{\%}) cases and 4 point mutations in exon 5 (E99K, D106N), intro 6 to exon 7 (AATA(G)), and exon 9 (A359T) of PTEN were found in 2 of the 30 (6.7{\%}) cases. PTEN loss was significantly more frequent in cases of trunk tumors, and the overexpression of EGFR was significantly more prevalent in patients who were 35 or older. Conclusions: PTEN deletion was associated with poor survival.",
keywords = "BRAF, EGFR, KRAS, PI3KCA, PTEN, synovial sarcoma",
author = "Teng, {Hao Wei} and Wang, {Hsei Wei} and Chen, {Wei Ming} and Chao, {Ta Chung} and Hsieh, {Yao Yu} and Hsih, {Chi Hsiu} and Tzeng, {Cheng Hwai} and Chen, {Paul Chih Hsueh} and Yen, {Chueh Chuan}",
year = "2011",
month = "6",
doi = "10.1002/jso.21852",
language = "English",
volume = "103",
pages = "773--781",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma

AU - Teng, Hao Wei

AU - Wang, Hsei Wei

AU - Chen, Wei Ming

AU - Chao, Ta Chung

AU - Hsieh, Yao Yu

AU - Hsih, Chi Hsiu

AU - Tzeng, Cheng Hwai

AU - Chen, Paul Chih Hsueh

AU - Yen, Chueh Chuan

PY - 2011/6

Y1 - 2011/6

N2 - Background We aimed to study the prevalence and prognostic influence of epidermal growth factor receptor (EGFR) and its downstream effectors in synovial sarcoma (SS). Objectives and Methods The tissue blocks from 30 patients were obtained. Expression of EGFR and phosphatase and tensin homolog (PTEN) were examined by immunohistochemistry, and mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, V-raf murine sarcoma viral oncogene homolog B1 (BRAF) exon 15, phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA) exons 9, 20, and PTEN exons 5-9 were analyzed by direct sequencing. Results: EGFR overexpression and PTEN deletion were found in 63.3% and 46.7% of patients. Sequence analysis failed to demonstrate mutations of KRAS and BRAF. However, an E545A point mutation in exon 9 of PI3KCA was found in 2 of the 30 (6.7%) cases and 4 point mutations in exon 5 (E99K, D106N), intro 6 to exon 7 (AATA(G)), and exon 9 (A359T) of PTEN were found in 2 of the 30 (6.7%) cases. PTEN loss was significantly more frequent in cases of trunk tumors, and the overexpression of EGFR was significantly more prevalent in patients who were 35 or older. Conclusions: PTEN deletion was associated with poor survival.

AB - Background We aimed to study the prevalence and prognostic influence of epidermal growth factor receptor (EGFR) and its downstream effectors in synovial sarcoma (SS). Objectives and Methods The tissue blocks from 30 patients were obtained. Expression of EGFR and phosphatase and tensin homolog (PTEN) were examined by immunohistochemistry, and mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, V-raf murine sarcoma viral oncogene homolog B1 (BRAF) exon 15, phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA) exons 9, 20, and PTEN exons 5-9 were analyzed by direct sequencing. Results: EGFR overexpression and PTEN deletion were found in 63.3% and 46.7% of patients. Sequence analysis failed to demonstrate mutations of KRAS and BRAF. However, an E545A point mutation in exon 9 of PI3KCA was found in 2 of the 30 (6.7%) cases and 4 point mutations in exon 5 (E99K, D106N), intro 6 to exon 7 (AATA(G)), and exon 9 (A359T) of PTEN were found in 2 of the 30 (6.7%) cases. PTEN loss was significantly more frequent in cases of trunk tumors, and the overexpression of EGFR was significantly more prevalent in patients who were 35 or older. Conclusions: PTEN deletion was associated with poor survival.

KW - BRAF

KW - EGFR

KW - KRAS

KW - PI3KCA

KW - PTEN

KW - synovial sarcoma

UR - http://www.scopus.com/inward/record.url?scp=79955695047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955695047&partnerID=8YFLogxK

U2 - 10.1002/jso.21852

DO - 10.1002/jso.21852

M3 - Article

VL - 103

SP - 773

EP - 781

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 8

ER -